Clinical Trial Update: Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating memantine for obsessive-compulsive disorder and generalized anxiety disorder has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder
• Obsessive-compulsive Disorder

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Obsessive-Compulsive Disorder, Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-05-10